Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + crizanlizumab
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of ruxolitinib (a small molecule Janus kinase 1 and 2 inhibitor) and crizanlizumab (a monoclonal antibody targeting P-selectin), evaluated in clinical trials for patients with myelofibrosis (MF) who exhibit suboptimal response to ruxolitinib monotherapy. Ruxolitinib disrupts cytokine signaling by inhibiting JAK1 and JAK2, thereby reducing inflammation and hematopoietic proliferation. Crizanlizumab blocks P-selectin on endothelial cells and platelets, inhibiting cell adhesion and potentially decreasing vascular occlusion and inflammation. This combination aims to target both myelofibrosis pathobiology and vascular/inflammatory complications[1][3][5][6].
02
Targets
Beyond the preview
Go deeper on ruxolitinib + crizanlizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + crizanlizumab.